First Light Asset Management LLC Purchases Shares of 693,044 LENZ Therapeutics, Inc. $LENZ

First Light Asset Management LLC purchased a new position in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 693,044 shares of the company’s stock, valued at approximately $32,282,000. LENZ Therapeutics makes up about 3.0% of First Light Asset Management LLC’s portfolio, making the stock its 10th biggest holding.

A number of other hedge funds have also recently made changes to their positions in LENZ. Geode Capital Management LLC grew its holdings in shares of LENZ Therapeutics by 15.5% during the 2nd quarter. Geode Capital Management LLC now owns 416,122 shares of the company’s stock valued at $12,198,000 after purchasing an additional 55,730 shares during the last quarter. Police & Firemen s Retirement System of New Jersey lifted its stake in LENZ Therapeutics by 63.6% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 4,130 shares of the company’s stock worth $121,000 after purchasing an additional 1,605 shares during the last quarter. Candriam S.C.A. bought a new stake in LENZ Therapeutics in the second quarter worth $5,020,000. Creative Planning purchased a new stake in LENZ Therapeutics during the second quarter valued at about $412,000. Finally, Intech Investment Management LLC boosted its position in LENZ Therapeutics by 4.3% during the second quarter. Intech Investment Management LLC now owns 9,251 shares of the company’s stock valued at $271,000 after buying an additional 380 shares during the period. 54.32% of the stock is currently owned by institutional investors.

LENZ Therapeutics Stock Performance

Shares of NASDAQ:LENZ opened at $12.15 on Monday. LENZ Therapeutics, Inc. has a 52-week low of $11.21 and a 52-week high of $50.40. The firm has a market capitalization of $380.17 million, a P/E ratio of -5.76 and a beta of 0.52. The stock has a 50 day moving average price of $15.01 and a 200-day moving average price of $25.91.

Wall Street Analyst Weigh In

LENZ has been the topic of a number of recent research reports. Wall Street Zen upgraded LENZ Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, March 1st. William Blair reissued an “outperform” rating on shares of LENZ Therapeutics in a research note on Tuesday, March 10th. HC Wainwright restated a “buy” rating on shares of LENZ Therapeutics in a research report on Monday, December 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of LENZ Therapeutics in a research note on Thursday, January 22nd. Finally, Zacks Research downgraded LENZ Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 20th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $56.40.

LENZ Therapeutics Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.